Shares of Cardiff Oncology, Inc. (NASDAQ: CRDF) were traded up 39.59% after it announced that Onvansertib has shown the clinical benefit in colorectal cancer. The company has presented data of Ovansertib at the European Society of Medical Oncology Virtual Congress. Cardiff Oncology is currently engaged in the Phase 1b/2clinical trial of Ovansertib Metastatic KRAS-mutated Colorectal Cancer.
In the Phase, 1b/2 study the company has checked the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab in second-line KRAS-mutated metastatic colorectal cancer. The Trial volunteers are treated with onvansertib on Days 1-5, and FOLFIRI and bevacizumab on Day 1, of 14-day treatment courses.
The company has disclosed that it has observed the benefit of treatment and during the treatment, the company saw no progression in the disease. The efficacy data gave the company a green signal to continue the trial.
Cardiff disclosed that 91% of patients have shown the positive result after receiving the treatment and only one patient progressing in less than six months while on treatment. 5 (45%) patients have attained partial response (PR). 73% of the patients have shown durable responses ranging from 6 to >12 months and 4 patients remain on treatment. Onvansertib in combination with FOLFIRI/bevacizumab is safe and well-tolerated.
The first two onvansertib dose levels (12 and 15 mg/m2) have got the green signal. Additionally, four patients have received the onvansertib dose level of (18 mg/m2) and two more will be enrolled.
Cardiff Oncology, Inc. (NASDAQ: CRDF) shares were trading up 339.59% at $8.11 at the time of writing on Thursday. Cardiff Oncology, Inc. (CRDF) share price went from a low point around $0.70 to briefly over $8.29 in the past 52 weeks. It has moved up 1056.92% from its 52-weeks low and moved down -2.17% from its 52-weeks high. Cardiff Oncology, Inc.’s market cap has remained high, hitting $197.48 million at the time of writing.